Leerink Partnrs Brokers Lower Earnings Estimates for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Investment analysts at Leerink Partnrs reduced their Q3 2024 EPS estimates for shares of Enanta Pharmaceuticals in a research report issued to clients and investors on Monday, May 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of ($1.60) per share for the quarter, down from their prior forecast of ($1.46). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($1.38) EPS, FY2024 earnings at ($6.04) EPS, FY2025 earnings at ($4.70) EPS, FY2026 earnings at ($3.15) EPS and FY2027 earnings at ($1.55) EPS.

ENTA has been the subject of several other research reports. HC Wainwright lowered their price target on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday. JMP Securities cut their price target on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. reduced their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Hold” and an average price target of $19.00.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $12.76 on Thursday. The business has a fifty day moving average price of $14.88 and a 200-day moving average price of $12.08. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $28.25. The stock has a market capitalization of $269.95 million, a price-to-earnings ratio of -2.04 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million during the quarter, compared to analysts’ expectations of $22.74 million.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. lifted its stake in shares of Enanta Pharmaceuticals by 613.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock valued at $7,055,000 after purchasing an additional 543,111 shares during the period. Jump Financial LLC boosted its stake in shares of Enanta Pharmaceuticals by 41.5% during the 3rd quarter. Jump Financial LLC now owns 56,636 shares of the biotechnology company’s stock worth $633,000 after acquiring an additional 16,608 shares in the last quarter. Clearstead Advisors LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $57,000. Quantbot Technologies LP increased its stake in shares of Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Enanta Pharmaceuticals in the 3rd quarter worth about $698,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.